GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC decreased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,169 shares of the company’s stock after selling 142 shares during the quarter. Transcend Capital Advisors LLC’s holdings in GE HealthCare Technologies were worth $248,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. LGT Financial Advisors LLC increased its stake in GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock worth $25,000 after acquiring an additional 251 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in GE HealthCare Technologies during the third quarter worth $26,000. Ashton Thomas Securities LLC acquired a new stake in GE HealthCare Technologies during the third quarter worth $26,000. Darwin Wealth Management LLC acquired a new stake in GE HealthCare Technologies during the third quarter worth $31,000. Finally, Continuum Advisory LLC increased its stake in GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after acquiring an additional 168 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on GEHC. Wells Fargo & Company raised their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Citigroup lifted their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Trading Down 1.1 %

NASDAQ:GEHC opened at $91.09 on Monday. The firm has a market cap of $41.66 billion, a PE ratio of 21.04, a price-to-earnings-growth ratio of 3.19 and a beta of 1.15. The stock has a fifty day moving average price of $85.05 and a 200 day moving average price of $85.90. GE HealthCare Technologies Inc. has a 12-month low of $74.51 and a 12-month high of $94.80. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.19. The firm had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.